Last modified: December 20, 2022
- American Board of Thoracic Surgery
- American Board of Surgery
- Pleural Mesothelioma
- Lung Cancer
- Thymic Epithelial Tumors
- Esophageal Cancer
- Minimally Invasive Thoracic Surgery
About Dr. Hoang
Thoracic surgeon Dr. Chuong Hoang is leading a research team in developing new therapeutic strategies for thoracic malignancies for non-small cell lung cancer, thymic epithelial tumors and pleural mesothelioma.
His most recent work in the fight against mesothelioma is an intraoperative, spray-on hydrogel involving genetically engineered nanoparticles with the ability to specifically target and kill tumor cells.
Although still in its early stages of development, Hoang believes it could become a much-needed, long-awaited breakthrough.
“I’m excited by what we’ve seen so far,” Hoang said. “This could become a huge deal, a real game-changer in treating this disease.”
Hoang’s clinical expertise in thoracic surgery includes thymic tumors, tracheal cancers, esophageal cancer, pulmonary metastasis and mesothelioma. He often utilizes minimally invasive robotic surgery.
Before joining the National Cancer Institute, Hoang was an assistant professor at the Stanford University School of Medicine and medical director of the Stanford Cancer Center Tissue Bank. He also established a thoracic oncology laboratory investigating microRNA interactions in mesothelioma.
Dr. Hoang’s Role as an Expert Contributor on Asbestos.com
Hoang’s extensive experience and expertise with a rare cancer such as mesothelioma make him a perfect fit to review pages and author articles for Asbestos.com.
His help has been critical in assuring that content on these pages remains current, consistent and medically correct, making The Mesothelioma Center at Asbestos.com the nation’s most trusted mesothelioma resource.